ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1194

Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-Degree Relatives in Indigenous North American Populations

Elizabeth D. Ferucci1, Irene Smolik2, Tammy L. Choromanski3, David B. Robinson4, Marianna M. Newkirk5, Marvin J. Fritzler6, Antony Rosen7, Erika Darrah8 and Hani S. El-Gabalawy4, 1Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, 2Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, 3Alaska Native Tribal Health Consortium, Anchorage, AK, 4Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, 5Medicine, McGill University Health Centr, Montreal, QC, Canada, 6Medicine, University of Calgary, Calgary, AB, Canada, 7Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 8Division of Rheumatology, The Johns Hopkins University, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoantibodies and rheumatoid arthritis (RA), Native Americans

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumamtoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Antibodies directed against peptidylarginine deiminase type 4 (PAD-4) are present in a subset of patients with rheumatoid arthritis (RA) and are associated with more severe joint destruction.  These autoantibodies have been detected preceding the clinical diagnosis of RA in some patients.  The objective of this study is to determine whether anti-PAD-4 antibodies are present in first-degree relatives of RA patients in two indigenous North American (INA) populations with high prevalence of RA.

Methods: Participants were recruited from two INA populations.  We included RA patients (probands), their unaffected first-degree relatives (FDRs), and healthy controls, including both INA and Caucasian controls.  Participants were interviewed for the presence of joint symptoms and underwent a joint examination by a rheumatologist.  Sera were tested for the presence of anti-PAD-4 antibodies, anti-cyclic citrullinated peptide (CCP) antibodies, and rheumatoid factor (RF) IgM by ELISA.  HLA-DRB1 subtyping was performed and participants were classified according to the presence or absence of shared epitope alleles.

Results: Antibodies to PAD-4 were detected in 27 of 82 (32.9%) RA probands; 2 of 147 (1.4%) FDRs; and 0 of 64 controls, including 20 Caucasian and 44 INA controls (p <0.0001).  Anti-CCP antibodies were present in 26/27 (96.3%) of probands with anti-PAD-4, as compared to 42/54 (77.8%) of probands without anti-PAD-4 (p=0.05).   In the FDRs, anti-CCP was present in 39/144 (27.1%) and there was no overlap between positivity for anti-CCP and PAD-4.  None of the controls had anti-CCP antibodies detected.  CCP and RF were both positive in 80.8% of the probands, but the association between RF and PAD-4 positivity was not statistically significant (p=0.14).  One or more copy of an HLA-DRB1 shared epitope allele was present in 92% of probands and 82% of relatives (p=0.13), and there was no association between the presence of a shared epitope allele and PAD-4 positivity in probands (p=0.65) or relatives (p=1.0). 

Conclusion: Despite a significant prevalence of anti-CCP in FDRs of INA RA patients, anti-PAD-4 antibodies were almost exclusively found in existing RA, suggesting these autoantibodies may be highly specific for RA.  The prevalence of anti-PAD-4 antibodies in INA people with RA is similar to the prevalence described in other populations and these autoantibodies are strongly associated with anti-CCP in RA.


Disclosure:

E. D. Ferucci,
None;

I. Smolik,
None;

T. L. Choromanski,
None;

D. B. Robinson,
None;

M. M. Newkirk,
None;

M. J. Fritzler,

Inova Diagnostics, Inc.,

5;

A. Rosen,
None;

E. Darrah,
None;

H. S. El-Gabalawy,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-anti-peptidylarginine-deiminase-type-4-antibodies-in-rheumatoid-arthritis-and-unaffected-first-degree-relatives-in-indigenous-north-american-populations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies